Novartis North America pharma head
Executive Summary
Ludwig Hantson becomes head of Novartis' North America pharma business, the company announces April 10. Hantson, who led Novartis' Specialty Medicines Operating Unit, replaces Alex Gorsky effective immediately (1"The Pink Sheet," Feb. 25, 2008, In Brief). Among other challenges, Hantson will have to determine the best course of action for Novartis' DPP-4 inhibitor Galvus (vildagliptin) following an approvable letter in 2007